Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2029

Study Completion Date

June 1, 2029

Conditions
Sepsis and Septic ShockAcute Respiratory FailureKidney Transplant RecipientsImmunosuppressive Agents
Interventions
DRUG

Hydrocortisone Hemisuccinate: 200 mg per day.

The hydrocortisone hemisuccinate is a powder and solvent for injectable solution at 100 mg. The powder must be dissolved in the solvent to ensure final isotonicity. The solution must be used within 24 hours. The injection is performed as a slow direct IV injection, either via an electric syringe pump or as a bolus of 50 mg every 6 hours

OTHER

reduction of the level of immunosuppression

"In this arm, the usual immunosuppressive treatment of the patients will be discontinued.~Patients will receive hydrocortisone hemisuccinate 200 mg per day (slow direct intraveinous injection of 50 mg four times a day, or through an electric syringe pump)."

All Listed Sponsors
lead

University Hospital, Strasbourg, France

OTHER